Key terms

About ME

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in South San Francisco, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ME news

Apr 15 8:50pm ET 23andMe price target lowered to 47c from 85c at Citi by TipRanks Apr 15 8:40pm ET Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and 23andMe Holding (ME) by TipRanks Apr 11 9:14am ET WW appoints new executive leaders by TipRanks Mar 29 1:02pm ET 23andMe CAO Kathy Hibbs Retires, Guy Chayoun Steps In by TipRanks Mar 20 7:37am ET 23andMe initiates Phase 1 trial for 23ME-01473 by TipRanks Mar 19 8:14am ET 23andMe launches feature connecting customers to historic individuals by TipRanks Mar 06 7:36am ET 23andMe launches new genetic report on forms of cancer by TipRanks Feb 08 6:20am ET 23andMe price target lowered to 85c from 90c at Citi by TipRanks Feb 08 6:20am ET Analysts Conflicted on These Healthcare Names: Denali Therapeutics (DNLI), BridgeBio Pharma (BBIO) and 23andMe Holding (ME) by TipRanks Feb 07 8:55pm ET Buy Rating for 23andMe on Strategic Restructuring and Potential for Shareholder Value Enhancement by TipRanks Feb 07 4:13pm ET 23andMe reduces FY24 revenue view to $215M-$220M, consensus $245.45M by TipRanks Feb 07 4:05pm ET 23andMe reports Q3 EPS (58c), consensus (14c) by TipRanks Feb 07 2:20pm ET 23andMe weighs splitting consumer, therapeutics units, Bloomberg says by TipRanks Feb 01 1:06am ET Maintaining a Hold: Balancing 23andMe’s Innovative Therapeutic Prospects with Early-Stage Development Risks by TipRanks Jan 31 7:31am ET 23andMe announces FDA clearance of IND application for 23ME-01473 by TipRanks

No recent press releases are available for ME

ME Financials

1-year income & revenue

Key terms

ME Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ME Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming
Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images
Samuel Corum/Bloomberg/Getty Images
Geopolitical strife is roiling Wall Street. Here’s what investors are watching